Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.81 |
| ▸ | CA5A | P35218 | 1/20 | 0.69 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.66 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.66 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.62 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19843952 | 1.00 | NT5E (0.81) | NT5ELMNAHIF1ACA5AADORA2A | |
| SCHEMBL15472852 | 1.00 | NT5E (0.81) | NT5ELMNAHIF1ACA5AADORA2A | |
| SCHEMBL12629460 | 1.00 | NT5E (0.81) | NT5ELMNAHIF1ACA5AADORA2A | |
| SCHEMBL12571546 | 1.00 | NT5E (0.81) | NT5ELMNAHIF1ACA5AADORA2A | |
| SCHEMBL12667517 | 0.91 | NT5E (0.67) | NT5ELMNAHIF1ACA5AADORA2A | |
| SCHEMBL12223707 | 0.91 | NT5E (0.67) | NT5ELMNAHIF1ACA5AADORA2A | |
| SCHEMBL18349651 | 0.91 | NT5E (0.67) | NT5ELMNAHIF1ACA5AADORA2A | |
| SCHEMBL2404116 | 0.90 | NT5E (0.66) | NT5ELMNAHIF1ACA5AADORA2A | |
| Fludarabine SCHEMBL14031844 | 0.89 | LMNA (1.00) | NT5ELMNAHIF1ACA5AADORA2A | |
| Fludarabine SCHEMBL13046078 | 0.89 | LMNA (1.00) | NT5ELMNAHIF1ACA5AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160137685-A1 | NUCLEOSIDE PHOSPHORAMIDATES AND PHOSPHORAMIDITES | PATEL HASMUKH B (US) | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137685-A1 | NUCLEOSIDE PHOSPHORAMIDATES AND PHOSPHORAMIDITES | PNP, NTPCR, SLC29A1 | NT5E 36/4885LMNA 3879/4885HIF1A 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.